A Phase 2 interventional study of LEO 124249 and Vehicle in Alopecia Areata, sponsored by LEO Pharma. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.
Among the 98 studies in Alopecia Areata with a site in United States, this one is the 45th largest by enrollment of the 84 interventional ones that give a count, is one of 5 that started in 2016, is one of 42 in phase 2, and was the 26th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:
AbbVie · Sites in United States, Australia, Japan and 1 more country
Ages 6–17
Pfizer · Sites in United States, Canada, China and 2 more countries
Ages 12+
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18–60
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 12+
Almirall, S.A. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 48 · Phase 3 16 · Phase 4 8
First in 1997; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 46 across the 84 interventional studies, 2,300 across the 14 observational. Of the 60 that completed or were terminated, 42 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 98 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
LEO Pharma has 2 studies filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
10 of the studies in Alopecia Areata with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07029711Phase 3PfizerA Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | 2026-12-02 |
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
| NCT06826196Aldena TherapeuticsA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | 2026-11 |
| NCT07821216PfizerReal-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data | 2026-11-20 |
| NCT06602232Dren BioA Study of DR-01 in Subjects With Alopecia Areata and Vitiligo | 2027-05 |
Add all 10 to your calendar (.ics) → With an account.
Among the 98 studies in Alopecia Areata with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers.
The objectives of this clinical trial are to compare the efficacy of twice-daily topical LEO 124249 30 mg/g ointment with LEO 124249 ointment vehicle for 12 weeks in the treatment of hair loss in subjects with alopecia areata, to evaluate the safety of this treatment, to evaluate hair regrowth, to determine subject quality of life, and to explore disease mechanism and its biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LEO 124249 ointment 30 mg/g twice daily
Drug: LEO 124249
LEO 124249 ointment vehicle twice daily
Other: Vehicle
Also known as: LEO 124249 Ointment
Also known as: LEO 124249 Vehicle
Change in Severity of Alopecia Areata Tool (SALT) Score
The SALT score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.
Time frame: From baseline (Day 1) to Week 12 (Day 84)
Summary of Absolute SALT Score
The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. Summary of observed values of the absolute SALT score.
Time frame: At baseline (Day 1), Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Summary of Change in SALT Score
The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.
Time frame: From baseline (Day 1) to Week 4 (Day 28), Week 8 (Day 56), and Week 12 (Day 84)
Summary of Relative Change in SALT Score
The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.
Time frame: From baseline (Day 1) to Week 4 (Day 28), Week 8 (Day 56), and Week 12 (Day 84)
Percentage of Patients Who Achieve 50% Improvement in the SALT Score
The event of having at least 50% reduction in SALT score at Week 12 (Day 84) as compared to baseline (Day 1)
Time frame: At Week 12 (Day 84)
Hair Length
Hair length measured in millimeters.
Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Hair Growth Rate
Change in hair length measured in millimeters per day.
Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Relative Hair Thickness
Thickness relative to participant's normal scalp hair. Relative assessment not applicable for participants with alopecia areata totalis and universalis.
Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Hair Type
Hair type being either vellus hair or terminal hair. Hair type is not applicable for participants with alopecia areata totalis and universalis.
Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Hair Color
Absolute color of hair. Hair color is not applicable for alopecia areata totalis and universalis.
Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Global Assessment of Overall Hair Regrowth Compared to Baseline
Based on standardized photographs
Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Participant's Global Assessment of Hair Regrowth
The participant will assess the hair regrowth before the investigator does any assessments of hair regrowth.
Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)
Subcategory and Total Score of the Alopecia Areata Quality of Life Questionnaire (AA-QLI)
The scale includes 21 questions measuring the degree to which the patient was affected by the AA in the last month, scored from 1 (not affected at all) to 4 (highly affected). The AA-QLI transformed scores for each of the subcategories 'subjective symptoms', 'relationship' and 'objective signs' ranging from (min-max) 9-36, 9-36, and 3-12. Total score ranges from 0-84. Low score indicating that the participant was least affected by AA.
Time frame: At baseline (Day 1) and at Week 12 (Day 84)
Treatment Satisfaction Questionnaire for Medication Score
The Treatment Satisfaction Questionnaire for Medication (TSQM II) is a validated, general measure of treatment satisfaction for medication - accounting for effectiveness, side effects, convenience, and global satisfaction - that is comparable across medication types and patient conditions. The individual derived score for each of the 4 dimensions (effectiveness, side effects, convenience, and global satisfaction) of the TSQM II questionnaire ranged from 0-100, with a higher score indicating greater satisfaction to treatment.
Time frame: At Week 12 (Day 84)
Date of First Subject First Visit: 02-Feb-2016 Date of Last Subject Last Visit: 06-Dec-2016
| Milestone | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Started | 20 | 11 |
| Completed | 17 | 6 |
| Not completed | 3 | 5 |
The SALT score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.
| units on a scale | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Change in Severity of Alopecia Areata Tool (SALT) Score | -3.8 ± 9.3 | -3.4 ± 17.0 |
The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. Summary of observed values of the absolute SALT score.
| units on a scale | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Baseline (Day 1) | 67.2 ± 25.1 | 74.4 ± 24.3 |
| Week 4 (Day 28) | 63.1 ± 26.7 | 71.0 ± 25.9 |
| Week 8 (Day 56) | 62.7 ± 27.5 | 68.6 ± 31.2 |
| Week 12 (Day 84) | 61.2 ± 28.9 | 66.4 ± 38.0 |
The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.
| units on a scale | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Baseline (Day 1) to Week 4 (Day 28) | -2.2 ± 4.4 | 0.0 ± 1.3 |
| Baseline (Day 1) to Week 8 (Day 56) | -2.5 ± 7.3 | -1.5 ± 9.6 |
| Baseline (Day 1) to Week 12 (Day 84) | -3.8 ± 9.3 | -3.4 ± 17.0 |
The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.
| percentage change | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Baseline (Day 1) to Week 4 (Day 28) | -4.6 ± 9.0 | -0.3 ± 2.3 |
| Baseline (Day 1) to Week 8 (Day 56) | -5.6 ± 17.8 | -5.3 ± 16.9 |
| Baseline (Day 1) to Week 12 (Day 84) | -7.7 ± 22.3 | -9.1 ± 32.5 |
The event of having at least 50% reduction in SALT score at Week 12 (Day 84) as compared to baseline (Day 1)
| Participants | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Yes | 2 | 1 |
| No | 15 | 5 |
Hair length measured in millimeters.
| mm | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Week 4 (Day 28) | 12.7 ± 17.0 | 5.6 ± 8.4 |
| Week 8 (Day 56) | 18.2 ± 21.7 | 10.3 ± 16.9 |
| Week 12 (Day 84) | 25.1 ± 31.8 | 16.3 ± 23.5 |
Change in hair length measured in millimeters per day.
| mm/day | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Week 4 (Day 28) | 0.4 ± 0.7 | 0.1 ± 0.2 |
| Week 8 (Day 56) | 0.2 ± 0.3 | 0.1 ± 0.5 |
| Week 12 (Day 84) | 0.3 ± 0.8 | 0.1 ± 0.5 |
Thickness relative to participant's normal scalp hair. Relative assessment not applicable for participants with alopecia areata totalis and universalis.
| Participants | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Week 4 (Day 28) — Much thinner | 10 | 1 |
| Week 4 (Day 28) — Slightly thinner | 1 | 0 |
| Week 4 (Day 28) — Same thickness | 0 | 0 |
| Week 8 (Day 56) — Much thinner | 6 | 1 |
| Week 8 (Day 56) — Slightly thinner | 1 | 1 |
| Week 8 (Day 56) — Same thickness | 1 | 0 |
| Week 12 (Day 84) — Much thinner | 4 | 1 |
| Week 12 (Day 84) — Slightly thinner | 1 | 1 |
| Week 12 (Day 84) — Same thickness | 1 | 0 |
Hair type being either vellus hair or terminal hair. Hair type is not applicable for participants with alopecia areata totalis and universalis.
| Participants | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Week 4 (Day 28) — Terminal hair | 4 | 1 |
| Week 4 (Day 28) — Velus hair | 9 | 2 |
| Week 8 (Day 56) — Terminal hair | 4 | 2 |
| Week 8 (Day 56) — Velus hair | 9 | 1 |
| Week 12 (Day 84) — Terminal hair | 6 | 1 |
| Week 12 (Day 84) — Velus hair | 6 | 2 |
Absolute color of hair. Hair color is not applicable for alopecia areata totalis and universalis.
| Participants | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Week 4 (Day 28) — Black | 4 | 1 |
| Week 4 (Day 28) — Blond | 2 | 1 |
| Week 4 (Day 28) — Brown | 3 | 0 |
| Week 4 (Day 28) — Gray | 0 | 0 |
| Week 4 (Day 28) — Red | 0 | 0 |
| Week 4 (Day 28) — White | 5 | 1 |
| Week 8 (Day 56) — Black | 4 | 1 |
| Week 8 (Day 56) — Blond | 1 | 0 |
| Week 8 (Day 56) — Brown | 4 | 0 |
| Week 8 (Day 56) — Gray | 0 | 1 |
| Week 8 (Day 56) — Red | 0 | 0 |
| Week 8 (Day 56) — White | 5 | 1 |
| Week 12 (Day 84) — Black | 4 | 0 |
| Week 12 (Day 84) — Blond | 1 | 0 |
| Week 12 (Day 84) — Brown | 2 | 0 |
| Week 12 (Day 84) — Gray | 0 | 0 |
| Week 12 (Day 84) — Red | 1 | 0 |
| Week 12 (Day 84) — White | 4 | 3 |
Based on standardized photographs
| Participants | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Week 4 (Day 28) — Much worse | 0 | 0 |
| Week 4 (Day 28) — Moderately worse | 1 | 0 |
| Week 4 (Day 28) — Slightly worse | 1 | 1 |
| Week 4 (Day 28) — Unchanged | 15 | 8 |
| Week 4 (Day 28) — Slightly improved | 2 | 0 |
| Week 4 (Day 28) — Moderately improved | 0 | 0 |
| Week 4 (Day 28) — Much improved | 0 | 0 |
| Week 8 (Day 56) — Much worse | 0 | 0 |
| Week 8 (Day 56) — Moderately worse | 0 | 1 |
| Week 8 (Day 56) — Slightly worse | 2 | 0 |
| Week 8 (Day 56) — Unchanged | 14 | 5 |
| Week 8 (Day 56) — Slightly improved | 2 | 0 |
| Week 8 (Day 56) — Moderately improved | 0 | 1 |
| Week 8 (Day 56) — Much improved | 0 | 0 |
| Week 12 (Day 84) — Much worse | 0 | 1 |
| Week 12 (Day 84) — Moderately worse | 0 | 0 |
| Week 12 (Day 84) — Slightly worse | 2 | 0 |
| Week 12 (Day 84) — Unchanged | 9 | 4 |
| Week 12 (Day 84) — Slightly improved | 5 | 0 |
| Week 12 (Day 84) — Moderately improved | 1 | 1 |
| Week 12 (Day 84) — Much improved | 0 | 0 |
The participant will assess the hair regrowth before the investigator does any assessments of hair regrowth.
| Participants | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Week 4 (Day 28) — No regrowth | 8 | 6 |
| Week 4 (Day 28) — <25% of regrowth | 8 | 3 |
| Week 4 (Day 28) — 25%-49% of regrowth | 2 | 0 |
| Week 4 (Day 28) — 50%-74% of regrowth | 0 | 0 |
| Week 4 (Day 28) — 75%-99% of regrowth | 0 | 0 |
| Week 4 (Day 28) — 100% of regrowth | 0 | 0 |
| Week 8 (Day 56) — No regrowth | 8 | 5 |
| Week 8 (Day 56) — <25% of regrowth | 8 | 1 |
| Week 8 (Day 56) — 25%-49% of regrowth | 0 | 1 |
| Week 8 (Day 56) — 50%-74% of regrowth | 2 | 0 |
| Week 8 (Day 56) — 75%-99% of regrowth | 0 | 0 |
| Week 8 (Day 56) — 100% of regrowth | 0 | 0 |
| Week 12 (Day 84) — No regrowth | 6 | 3 |
| Week 12 (Day 84) — <25% of regrowth | 8 | 1 |
| Week 12 (Day 84) — 25%-49% of regrowth | 1 | 1 |
| Week 12 (Day 84) — 50%-74% of regrowth | 2 | 1 |
| Week 12 (Day 84) — 75%-99% of regrowth | 0 | 0 |
| Week 12 (Day 84) — 100% of regrowth | 0 | 0 |
The scale includes 21 questions measuring the degree to which the patient was affected by the AA in the last month, scored from 1 (not affected at all) to 4 (highly affected). The AA-QLI transformed scores for each of the subcategories 'subjective symptoms', 'relationship' and 'objective signs' ranging from (min-max) 9-36, 9-36, and 3-12. Total score ranges from 0-84. Low score indicating that the participant was least affected by AA.
| units on a scale | Baseline: LEO 124249 | Baseline: LEO 124249 Vehicle | Week 12: LEO 124249 | Week 12: LEO 124249 Vehicle |
|---|---|---|---|---|
| Subjective symptoms | 25.9 ± 4.9 | 24.3 ± 5.5 | 25.5 ± 4.4 | 23.7 ± 7.3 |
| Relationship | 18.7 ± 6.8 | 17.5 ± 6.7 | 18.7 ± 7.2 | 16.8 ± 7.5 |
| Objective signs | 7.8 ± 2.4 | 8.4 ± 2.2 | 6.9 ± 2.3 | 7.7 ± 2.7 |
| Total score | 52.3 ± 12.1 | 50.2 ± 11.1 | 51.1 ± 12.5 | 48.2 ± 15.2 |
The Treatment Satisfaction Questionnaire for Medication (TSQM II) is a validated, general measure of treatment satisfaction for medication - accounting for effectiveness, side effects, convenience, and global satisfaction - that is comparable across medication types and patient conditions. The individual derived score for each of the 4 dimensions (effectiveness, side effects, convenience, and global satisfaction) of the TSQM II questionnaire ranged from 0-100, with a higher score indicating greater satisfaction to treatment.
| units on a scale | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| Effectiveness | 28.9 ± 23.2 | 41.7 ± 12.9 |
| Side effects | 94.5 ± 15.1 | 100.0 ± 0.0 |
| Convenience | 52.3 ± 17.7 | 54.6 ± 21.8 |
| Global satisfaction | 40.7 ± 22.6 | 47.2 ± 22.8 |
Collected over From screening (within 28 days prior to Day 1) to end of trial (Week 14). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LEO 124249 | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| LEO 124249 Vehicle | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Event | LEO 124249 | LEO 124249 Vehicle |
|---|---|---|
| FolliculitisInfections and infestations | 2/20 | 0/11 |
| Upper respiratory tract infectionInfections and infestations | 0/20 | 1/11 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/20 | 1/11 |
| ConjunctivitisInfections and infestations | 1/20 | 0/11 |
| LymphadenopathyBlood and lymphatic system disorders | 1/20 | 0/11 |
| FatigueGeneral disorders | 1/20 | 0/11 |
| Age, Categorical(Participants) | LEO 124249 | LEO 124249 Vehicle | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 11 | 31 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | LEO 124249 | LEO 124249 Vehicle | Total |
|---|---|---|---|
| Mean | 36.4 ± 14.0 | 32.1 ± 8.2 | 34.9 ± 12.3 |
| Sex: Female, Male(Participants) | LEO 124249 | LEO 124249 Vehicle | Total |
|---|---|---|---|
| Female | 14 | 5 | 19 |
| Male | 6 | 6 | 12 |
| Region of Enrollment(Participants) | LEO 124249 | LEO 124249 Vehicle | Total |
|---|---|---|---|
| United States | 20 | 11 | 31 |
Plan to share: No
The record gives a start of Jan 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2019, 2 years 4 months after primary completion. A results delay was requested in Nov 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib